Stanley Druckenmiller Bei Gene, Ltd. Transaction History

Duquesne Family Office LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $6.87 Million - $9.82 Million	-31,025 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$189.18 - $286.44 $916,577 - $1.39 Million	4,845 Added 18.51%	31,025 $8.89 Million
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $3.24 Million - $5.12 Million	26,180 New	26,180 $4.93 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.1B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Duquesne Family Office LLC, based on Form 13F filings with the SEC.

Stay updated on Duquesne Family Office LLC and Stanley Druckenmiller with notifications on news.